Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Melnyk, Anton
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations	Active, not recruiting	2	217	Europe, Japan, US, RoW	tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex	Seagen Inc., Seagen, Inc.	Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms	11/23	05/25
Garcia, Rebecca
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry	Active, not recruiting	N/A	3465	US	Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test	Biotheranostics, Inc.	Breast Cancer	12/28	12/28